33 research outputs found
Observation of decays using the 2019-2022 Belle II data sample
We present a measurement of the branching fractions of four decay modes. The measurement is based on data from
SuperKEKB electron-positron collisions at the resonance
collected with the Belle II detector and corresponding to an integrated
luminosity of . The event yields are extracted from fits
to the distributions of the difference between expected and observed meson
energy to separate signal and background, and are efficiency-corrected as a
function of the invariant mass of the system. We find the branching
fractions to be: where the first uncertainty is statistical and
the second systematic. These results include the first observation of
, , and decays and a significant improvement in the precision
of compared to previous measurements
Measurement of the branching fraction for the decay at Belle II
We report a measurement of the branching fraction of decays, where or
, using electron-positron collisions recorded at an energy at or near
the mass and corresponding to an integrated luminosity of
fb. The data was collected during 2019--2021 by the Belle II experiment
at the SuperKEKB asymmetric-energy collider. We reconstruct
candidates in the , , and
final states. The signal yields with statistical uncertainties are ,
, and for the decays , , and , respectively.
We measure the branching fractions of these decays for the entire range of the
dilepton mass, excluding the very low mass region to suppress the background and regions compatible with decays
of charmonium resonances, to be \begin{equation} {\cal B}(B \to
K^{\ast}(892)\mu^+\mu^-) = (1.19 \pm 0.31 ^{+0.08}_{-0.07}) \times 10^{-6},
{\cal B}(B \to K^{\ast}(892)e^+e^-) = (1.42 \pm 0.48 \pm 0.09)\times 10^{-6},
{\cal B}(B \to K^{\ast}(892)\ell^+\ell^-) = (1.25 \pm 0.30 ^{+0.08}_{-0.07})
\times 10^{-6}, \end{equation} where the first and second uncertainties are
statistical and systematic, respectively. These results, limited by sample
size, are the first measurements of branching
fractions from the Belle II experiment
Angular analysis of decays reconstructed in 2019, 2020, and 2021 Belle II data
We report on a Belle II measurement of the branching fraction
(), longitudinal polarization fraction (), and CP asymmetry
() of decays. We reconstruct decays in a
sample of SuperKEKB electron-positron collisions collected by the Belle II
experiment in 2019, 2020, and 2021 at the (4S) resonance and
corresponding to 190 fb of integrated luminosity. We fit the
distributions of the difference between expected and observed candidate
energy, continuum-suppression discriminant, dipion masses, and decay angles of
the selected samples, to determine a signal yield of events. The
signal yields are corrected for efficiencies determined from simulation and
control data samples to obtain $\mathcal{B}(B^+ \to \rho^+\rho^0) = [23.2^{+\
2.2}_{-\ 2.1} (\rm stat) \pm 2.7 (\rm syst)]\times 10^{-6}f_L = 0.943 ^{+\
0.035}_{-\ 0.033} (\rm stat)\pm 0.027(\rm syst)\mathcal{A}_{CP}=-0.069
\pm 0.068(\rm stat) \pm 0.060 (\rm syst)\mathcal{A}_{CP}B^+\to
\rho^+\rho^0$ decays reported by Belle II
Reconstruction of decays identified using hadronic decays of the recoil meson in 2019 -- 2021 Belle II data
We present results on the semileptonic decays and in a sample corresponding to
189.9/fb of Belle II data at the SuperKEKB collider. Signal decays
are identified using full reconstruction of the recoil meson in hadronic
final states. We determine the total branching fractions via fits to the
distributions of the square of the "missing" mass in the event and the dipion
mass in the signal candidate and find and where the dominant
systematic uncertainty comes from modeling the nonresonant contribution
Measurement of the branching fractions and asymmetries of and decays in 2019-2021 Belle II data
We determine the branching fractions and asymmetries
of the decays and . The results are based on a data set containing 198
million bottom-antibottom meson pairs corresponding to an integrated luminosity
of recorded by the Belle II detector in energy-asymmetric
electron-positron collisions at the resonance. We measure
, , , and , where the first uncertainties are
statistical and the second are systematic. These results improve a previous
Belle II measurement and agree with the world averages
Large expert-curated database for benchmarking document similarity detection in biomedical literature search
Document recommendation systems for locating relevant literature have mostly relied on methods developed a decade ago. This is largely due to the lack of a large offline gold-standard benchmark of relevant documents that cover a variety of research fields such that newly developed literature search techniques can be compared, improved and translated into practice. To overcome this bottleneck, we have established the RElevant LIterature SearcH consortium consisting of more than 1500 scientists from 84 countries, who have collectively annotated the relevance of over 180 000 PubMed-listed articles with regard to their respective seed (input) article/s. The majority of annotations were contributed by highly experienced, original authors of the seed articles. The collected data cover 76% of all unique PubMed Medical Subject Headings descriptors. No systematic biases were observed across different experience levels, research fields or time spent on annotations. More importantly, annotations of the same document pairs contributed by different scientists were highly concordant. We further show that the three representative baseline methods used to generate recommended articles for evaluation (Okapi Best Matching 25, Term Frequency-Inverse Document Frequency and PubMed Related Articles) had similar overall performances. Additionally, we found that these methods each tend to produce distinct collections of recommended articles, suggesting that a hybrid method may be required to completely capture all relevant articles. The established database server located at https://relishdb.ict.griffith.edu.au is freely available for the downloading of annotation data and the blind testing of new methods. We expect that this benchmark will be useful for stimulating the development of new powerful techniques for title and title/abstract-based search engines for relevant articles in biomedical research.Peer reviewe
Recommended from our members
Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
BACKGROUND Regular, detailed reporting on population health by underlying cause of death is fundamental for public health decision making. Cause-specific estimates of mortality and the subsequent effects on life expectancy worldwide are valuable metrics to gauge progress in reducing mortality rates. These estimates are particularly important following large-scale mortality spikes, such as the COVID-19 pandemic. When systematically analysed, mortality rates and life expectancy allow comparisons of the consequences of causes of death globally and over time, providing a nuanced understanding of the effect of these causes on global populations. METHODS The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 cause-of-death analysis estimated mortality and years of life lost (YLLs) from 288 causes of death by age-sex-location-year in 204 countries and territories and 811 subnational locations for each year from 1990 until 2021. The analysis used 56 604 data sources, including data from vital registration and verbal autopsy as well as surveys, censuses, surveillance systems, and cancer registries, among others. As with previous GBD rounds, cause-specific death rates for most causes were estimated using the Cause of Death Ensemble model-a modelling tool developed for GBD to assess the out-of-sample predictive validity of different statistical models and covariate permutations and combine those results to produce cause-specific mortality estimates-with alternative strategies adapted to model causes with insufficient data, substantial changes in reporting over the study period, or unusual epidemiology. YLLs were computed as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 1000-draw distribution for each metric. We decomposed life expectancy by cause of death, location, and year to show cause-specific effects on life expectancy from 1990 to 2021. We also used the coefficient of variation and the fraction of population affected by 90% of deaths to highlight concentrations of mortality. Findings are reported in counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2021 include the expansion of under-5-years age group to include four new age groups, enhanced methods to account for stochastic variation of sparse data, and the inclusion of COVID-19 and other pandemic-related mortality-which includes excess mortality associated with the pandemic, excluding COVID-19, lower respiratory infections, measles, malaria, and pertussis. For this analysis, 199 new country-years of vital registration cause-of-death data, 5 country-years of surveillance data, 21 country-years of verbal autopsy data, and 94 country-years of other data types were added to those used in previous GBD rounds. FINDINGS The leading causes of age-standardised deaths globally were the same in 2019 as they were in 1990; in descending order, these were, ischaemic heart disease, stroke, chronic obstructive pulmonary disease, and lower respiratory infections. In 2021, however, COVID-19 replaced stroke as the second-leading age-standardised cause of death, with 94·0 deaths (95% UI 89·2-100·0) per 100 000 population. The COVID-19 pandemic shifted the rankings of the leading five causes, lowering stroke to the third-leading and chronic obstructive pulmonary disease to the fourth-leading position. In 2021, the highest age-standardised death rates from COVID-19 occurred in sub-Saharan Africa (271·0 deaths [250·1-290·7] per 100 000 population) and Latin America and the Caribbean (195·4 deaths [182·1-211·4] per 100 000 population). The lowest age-standardised death rates from COVID-19 were in the high-income super-region (48·1 deaths [47·4-48·8] per 100 000 population) and southeast Asia, east Asia, and Oceania (23·2 deaths [16·3-37·2] per 100 000 population). Globally, life expectancy steadily improved between 1990 and 2019 for 18 of the 22 investigated causes. Decomposition of global and regional life expectancy showed the positive effect that reductions in deaths from enteric infections, lower respiratory infections, stroke, and neonatal deaths, among others have contributed to improved survival over the study period. However, a net reduction of 1·6 years occurred in global life expectancy between 2019 and 2021, primarily due to increased death rates from COVID-19 and other pandemic-related mortality. Life expectancy was highly variable between super-regions over the study period, with southeast Asia, east Asia, and Oceania gaining 8·3 years (6·7-9·9) overall, while having the smallest reduction in life expectancy due to COVID-19 (0·4 years). The largest reduction in life expectancy due to COVID-19 occurred in Latin America and the Caribbean (3·6 years). Additionally, 53 of the 288 causes of death were highly concentrated in locations with less than 50% of the global population as of 2021, and these causes of death became progressively more concentrated since 1990, when only 44 causes showed this pattern. The concentration phenomenon is discussed heuristically with respect to enteric and lower respiratory infections, malaria, HIV/AIDS, neonatal disorders, tuberculosis, and measles. INTERPRETATION Long-standing gains in life expectancy and reductions in many of the leading causes of death have been disrupted by the COVID-19 pandemic, the adverse effects of which were spread unevenly among populations. Despite the pandemic, there has been continued progress in combatting several notable causes of death, leading to improved global life expectancy over the study period. Each of the seven GBD super-regions showed an overall improvement from 1990 and 2021, obscuring the negative effect in the years of the pandemic. Additionally, our findings regarding regional variation in causes of death driving increases in life expectancy hold clear policy utility. Analyses of shifting mortality trends reveal that several causes, once widespread globally, are now increasingly concentrated geographically. These changes in mortality concentration, alongside further investigation of changing risks, interventions, and relevant policy, present an important opportunity to deepen our understanding of mortality-reduction strategies. Examining patterns in mortality concentration might reveal areas where successful public health interventions have been implemented. Translating these successes to locations where certain causes of death remain entrenched can inform policies that work to improve life expectancy for people everywhere. FUNDING Bill & Melinda Gates Foundation